Efficacy and safety of omalizumab combined with allergen immunotherapy in children with moderate to severe allergic asthma.

IF 7.2 2区医学 Q1 OTORHINOLARYNGOLOGY

International Forum of Allergy & Rhinology Pub Date : 2024-10-15 DOI:10.1002/alr.23470

Wenxin Shen, Qianlan Zhou, Qinzhen Zhang, Lina Han, Li Chen, Xiaowen Li, Bing Dai, Si Liu, Lishen Shan

引用次数: 0

Abstract

Key points: Omalizumab enables children who are intolerant to AIT to initiate AIT successfully. Combination therapy better improves asthma and rhinitis symptoms, FeNO, and lung function compared to single SCIT or omalizumab treatment. Combination therapy reduces the incidence of adverse reactions during the initial phase of SCIT and enhances its safety.

查看原文本刊更多论文

奥马珠单抗联合过敏原免疫疗法对中重度过敏性哮喘患儿的疗效和安全性。

要点奥马珠单抗能让对 AIT 不耐受的儿童成功启动 AIT。与单一SCIT或奥马珠单抗治疗相比，联合疗法能更好地改善哮喘和鼻炎症状、FeNO和肺功能。联合疗法降低了SCIT初始阶段不良反应的发生率，提高了安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Forum of Allergy & Rhinology OTORHINOLARYNGOLOGY-

CiteScore

11.70

自引率

10.90%

发文量

185

审稿时长

6-12 weeks

期刊介绍： International Forum of Allergy & Rhinologyis a peer-reviewed scientific journal, and the Official Journal of the American Rhinologic Society and the American Academy of Otolaryngic Allergy. International Forum of Allergy Rhinology provides a forum for clinical researchers, basic scientists, clinicians, and others to publish original research and explore controversies in the medical and surgical treatment of patients with otolaryngic allergy, rhinologic, and skull base conditions. The application of current research to the management of otolaryngic allergy, rhinologic, and skull base diseases and the need for further investigation will be highlighted.